To get an idea of who really controls Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14), it is important to understand the ownership structure of the company. And the group that holds the biggest slice of the pie are individual investors with 49% ownership. That is, the group will benefit the most if the stock goes up (or lose the most if there is a downturn).
As a result, individual investors collectively scored the highest last week as the company hit a market capitalization of US$2.0 billion after the stock gained 7.6%.
Let’s dive deeper into each type of owner in Tianjin Pharmaceutical Da Ren Tang Group, starting with the table below.
Check opportunities and risks within the SG Pharmaceuticals industry.
What does institutional ownership tell us about Tianjin Pharmaceutical Da Ren Tang Group?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it is included in a major index. We would expect most companies to have some institutions listed, especially if they are growing.
As you can see, institutional investors hold a sizeable share of Tianjin Pharmaceutical Da Ren Tang Group. This suggests some credibility with professional investors. But we cannot rely solely on this fact since institutions sometimes make bad investments, like everyone else. It is not uncommon to see a sharp decline in the stock price if two large institutional investors attempt to sell a stock at the same time. It is therefore worth checking the past earnings trajectory of Tianjin Pharmaceutical Da Ren Tang Group (below). Of course, keep in mind that there are other factors to consider as well.
Tianjin Pharmaceutical Da Ren Tang Group is not owned by hedge funds. Jinhushen Biomedical Technology Co., Ltd. is currently the largest shareholder, with 43% of the outstanding shares. Meanwhile, the second and third largest shareholders hold 1.1% and 0.9% of the outstanding shares respectively.
After digging a little deeper, we found that the top 22 held combined ownership of 50% of the company, suggesting that no single shareholder has significant control over the company.
While it makes sense to study data on a company’s institutional ownership, it also makes sense to study analyst sentiment to find out which way the wind is blowing. Our information suggests there is no analyst coverage of the stock, so it is likely little known.
Insider ownership of Tianjin Pharmaceutical Da Ren Tang Group
The definition of company insiders can be subjective and varies from jurisdiction to jurisdiction. Our data reflects individual insiders, capturing at least board members. The management of the company runs the company, but the CEO will answer to the board of directors, even if he is a member of it.
Most view insider ownership as a positive because it can indicate that the board is well aligned with other shareholders. However, there are times when too much power is concentrated within this group.
We may report that insiders hold shares of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited. This is a big company, so it’s good to see this level of alignment. Insiders hold $40 million worth of stock (at current prices). If you want to explore the issue of insider alignment, you can click here to see if insiders have been buying or selling.
General public property
The general public, who are usually individual investors, hold a 49% stake in Tianjin Pharmaceutical Da Ren Tang Group. While that size of ownership might not be enough to sway a policy decision in their favor, they can still have a collective impact on company policies.
Private Company Ownership
Our data indicates that private companies hold 43% of the shares of society. Private companies can be related parties. Sometimes insiders have an interest in a public company through an equity stake in a private company, rather than in their own capacity as individuals. Although it is difficult to draw general conclusions, it should be noted that this is an area for further research.
It is always useful to think about the different groups that own shares in a company. But to better understand the Tianjin Pharmaceutical Da Ren Tang Group, we need to consider many other factors. For example, we have identified 1 warning sign for Tianjin Pharmaceutical Da Ren Tang Group of which you should be aware.
If you’d rather check out another company – one with potentially superior finances – then don’t miss this free list of interesting companies, supported by solid financial data.
NB: The figures in this article are calculated using trailing twelve month data, which refers to the 12 month period ending on the last day of the month the financial statements are dated. This may not be consistent with the annual report figures for the full year.
Feedback on this article? Concerned about content? Get in touch with us directly. You can also email the editorial team (at) Simplywallst.com.
This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.
Valuation is complex, but we help make it simple.
Find out if Tianjin Da Ren Tang Pharmaceutical Group is potentially overvalued or undervalued by viewing our full analysis, which includes fair value estimates, risks and warnings, dividends, insider trading and financial health.
See the free analysis